Korean drug maker Celltrion has announced that it has resubmitted its Biologics License Application for CT-P6, a trastuzumab molecule referencing Herceptin. Separately, Celltrion announced new data for its proposed subcutaneous formulation of its flagship biosimilar, CT-P13, an infliximab biosimilar referencing Remicade, in patients with rheumatoid arthritis.
After having received Complete Response Letters (CRL) in April 2018 for 2 proposed biosimilars, Korean drug maker Celltrion has announced that it has resubmitted its Biologics License Application (BLA) for CT-P6, a trastuzumab molecule referencing Herceptin. Last month, the company resubmitted its BLA for CT-P10, a rituximab biosimilar referencing Rituxan.
According to a statement on Celltrion’s website, the FDA requested supplementary information about both products when it issued the CRLs, and the company worked closely with regulators to address issues identified in a February 2018 FDA warning letter related to manufacturing processes. In today's announcment about trastuzumab’s resubmission, Celltrion indicated that the FDA has notified the company of its reinspection schedule, and both molecules could potentially be approved by the FDA by the end of 2018.
Separately, Celltrion also announced new data for its proposed subcutaneous formulation of its flagship biosimilar, CT-P13 (sold in the United States as Inflectra and in the European Union as Remsima). During the European League Against Rheumatism's Annual European Congress of Rheumatology, held last week in Amsterdam, Netherlands, researchers reported that the company’s subcutaneous CT-P13, which can be self-administered, had similar efficacy and generally similar safety to the currently approved intravenous CT-P13 up to week 30 in patients with rheumatoid arthritis (RA).1
In a study of 48 patients with RA, who were assigned to receive either the intravenous infliximab or subcutaneous injections of 90 mg, 120 mg, or 180 mg of infliximab, disease improvement (assessed in terms of disease activity score in a count of 28 joints and the American College of Rheumatology’s criteria for 20% improvement) was comparable across all 4 treatment groups, regardless of route of administration or dosage.
Two patients experienced hypersensitivity reactions, and 1 of the 2 tested positive for anti-drug antibodies at week 6.
Earlier this month, Celltrion reported positive results from a phase 1 study of its subcutaneous formulation of the biosimilar in patients with Crohn disease. In that study, patients who received intravenous therapy and those who received subcutaneous doses of 120 mg, 180 mg, and 240 mg showed similar improvement in terms of Crohn Disease Activity Index score.
Currently, there are no subcutaneous infliximab options available to patients with inflammatory diseases; a self-administered option, if eventually approved, could allow patients greater flexibility in their treatment options for these diseases.
Reference
1. Westhovens R, Yoo DH, Jaworski J, et al. Novel formulation of CT-P13 for subcutaneous administration in patients with rheumatoid arthritis: initial results from a phase i/iii randomised controlled trial. Presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology, June 13-16, 2018; Amsterdam, Netherlands. Abstract THU0191. doi: 10.1136/annrheumdis-2018-eular.1810.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.